| Title |
18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, February 2012
|
| DOI | 10.1007/s00259-011-2037-0 |
| Pubmed ID | |
| Authors |
Kenji Hirata, Shunsuke Terasaka, Tohru Shiga, Naoya Hattori, Keiichi Magota, Hiroyuki Kobayashi, Shigeru Yamaguchi, Kiyohiro Houkin, Shinya Tanaka, Yuji Kuge, Nagara Tamaki |
| Abstract |
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor and its prognosis is significantly poorer than those of less malignant gliomas. Pathologically, necrosis is one of the most important characteristics that differentiate GBM from lower grade gliomas; therefore, we hypothesized that (18)F fluoromisonidazole (FMISO), a radiotracer for hypoxia imaging, accumulates in GBM but not in lower grade gliomas. We aimed to evaluate the diagnostic value of FMISO positron emission tomography (PET) for the differential diagnosis of GBM from lower grade gliomas. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| United Kingdom | 1 | 2% |
| Netherlands | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 53 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 16% |
| Student > Ph. D. Student | 8 | 14% |
| Student > Postgraduate | 6 | 11% |
| Professor > Associate Professor | 6 | 11% |
| Student > Master | 6 | 11% |
| Other | 15 | 26% |
| Unknown | 7 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 49% |
| Agricultural and Biological Sciences | 9 | 16% |
| Neuroscience | 4 | 7% |
| Engineering | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 3 | 5% |
| Unknown | 8 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2012.
All research outputs
#14,591,600
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#1,749
of 3,083 outputs
Outputs of similar age
#156,822
of 252,519 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#16
of 29 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,519 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.